Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Ajay K. Gopal

Oncology
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ajay Gopal is an Oncologist in Seattle, Washington. Dr. Gopal is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma. Dr. Gopal is currently accepting new patients.

His clinical research consists of co-authoring 206 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Specialties
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Castilian
Hindi
Punjabi
Spanish
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
325 9th Ave, Seattle, WA 98104
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma
Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Acalabrutinib, Axicabtagene Ciloleucel
Study Phase: Phase 1/Phase 2
A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma
A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Dacarbazine, Doxorubicin, Pembrolizumab, Vinblastine
Study Phase: Phase 1/Phase 2
A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin
A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)
A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Carboplatin, Etoposide, Ifosfamide
Study Phase: Phase 1/Phase 2
A Window Study of Ixazomib in Untreated Indolent B-NHL
A Window Study of Ixazomib in Untreated Indolent B-NHL
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Ixazomib, Rituximab
Study Phase: Phase 2
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Enrollment Status: Terminated
Publish Date: December 31, 2024
Intervention Type: Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Enrollment Status: Terminated
Publish Date: October 24, 2024
Intervention Type: Biological
Study Drug: GEN3009
Study Phase: Phase 1/Phase 2
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Nivolumab
Study Phase: Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide
Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide
Enrollment Status: Terminated
Publish Date: August 10, 2021
Intervention Type: Other, Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 20, 2021
Intervention Type: Radiation, Procedure, Biological, Drug, Other
Study Drugs: Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Rituximab, Fludarabine
Study Phase: Phase 2
Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies
Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies
Enrollment Status: Terminated
Publish Date: November 23, 2020
Intervention Type: Drug, Procedure, Radiation, Other, Biological
Study Phase: Phase 1
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Enrollment Status: Terminated
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies
A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies
Enrollment Status: Completed
Publish Date: August 04, 2020
Intervention Type: Radiation, Procedure, Drug, Other
Study Phase: Phase 1/Phase 2
View 16 Less Clinical Trials

206 Total Publications

Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma.
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025
Similar Doctors
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Ryan C. Lynch
Hematology Oncology | Hematology | Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Ryan C. Lynch
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Lynch is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Lynch is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant. Dr. Lynch is currently accepting new patients.

Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Mazyar S. Shadman
Hematology Oncology | Oncology | Hematology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Mazyar S. Shadman
Hematology Oncology | Oncology | Hematology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Farsi, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mazyar Shadman is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Shadman is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Shadman is currently accepting new patients.

David G. Maloney
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. David G. Maloney
Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. David G. Maloney
Oncology
1959 Ne Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-598-4100
Languages Spoken:
English, Castilian, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Maloney is an Oncologist in Seattle, Washington. Dr. Maloney is rated as an Elite provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL). Dr. Maloney is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gopal's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 12 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile